MAPT and Alzheimer disease: We further investigated the performance of the same panel to predict other AD endophenotypes in the combined cohort (combining groups one and two), including discriminating AD from HC and AD from MCI, differentiating status of t-tau, p-tau, MCI conversion, baseline MMSE score, hippocampal volume, and other three CSF biomarkers including NFL, neurogranin, and YKL-40.